Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Refractory Prostate Cancer Disease”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT03834493
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

Who this might be right for
Prostatic Neoplasms
Merck Sharp & Dohme LLC 1,244
Testing effectiveness (Phase 2)Study completedNCT00919035
What this trial is testing

Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients

Who this might be right for
Prostate Cancer
Oncology Specialists, S.C. 21
Testing effectiveness (Phase 2)Ended earlyNCT00786682
What this trial is testing

Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
University of Medicine and Dentistry of New Jersey 11
Testing effectiveness (Phase 2)WithdrawnNCT06527690
What this trial is testing

Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer

Who this might be right for
Prostate CancerCastrate Resistant Prostate CancerHomologous Recombination Deficiency
Latin American Cooperative Oncology Group
Early research (Phase 1)Ended earlyNCT05241613
What this trial is testing

AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Accutar Biotechnology Inc 28
Early research (Phase 1)Enrolling By InvitationNCT07583160
What this trial is testing

YS247 (Neoantigen-Pulsed DC Vaccine) for Metastatic Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer PatientsCastration-Resistant Prostate Cancer (CRPC)Prostate Neoplasms
Changhai Hospital 18
Not applicableStudy completedNCT02269982
What this trial is testing

Prospective CiRculating prOstate Cancer Predictors in HighEr Risk mCRPC studY

Who this might be right for
Prostate Cancer
Duke University 120
Early research (Phase 1)Looking for participantsNCT07277270
What this trial is testing

GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

Who this might be right for
Neoplasms
GlaxoSmithKline 83
Testing effectiveness (Phase 2)Looking for participantsNCT06970119
What this trial is testing

A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer

Who this might be right for
Prostate Cancer
Yunhe Pharmaceutical (Tianjin) Co., Ltd 55
Testing effectiveness (Phase 2)Ended earlyNCT00515112
What this trial is testing

Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
University of Chicago 6
Testing effectiveness (Phase 2)Ended earlyNCT01267266
What this trial is testing

Saracatinib in Treating Patients With Prostate Cancer

Who this might be right for
Hormone-resistant Prostate CancerRecurrent Prostate CancerStage IV Prostate Cancer
National Cancer Institute (NCI) 31
Not applicableWithdrawnNCT01692483
What this trial is testing

Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Prostate Neoplasms
Janssen Pharmaceutica
Early research (Phase 1)Study completedNCT00326586
What this trial is testing

A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Bristol-Myers Squibb 54
Not applicableStudy completedNCT02588001
What this trial is testing

Japanese Research for Patients With Non-metastatic Castration Resistant Prostate Cancer - Enzalutamide

Who this might be right for
Prostate Cancer
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan 60
Testing effectiveness (Phase 2)Study completedNCT03888612
What this trial is testing

Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Prostate Cancer Metastatic
Arvinas Inc. 248
Large-scale testing (Phase 3)WithdrawnNCT02053311
What this trial is testing

Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents

Who this might be right for
Prostate Cancer
Swiss Cancer Institute
Testing effectiveness (Phase 2)Ended earlyNCT04631601
What this trial is testing

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Amgen 55
Testing effectiveness (Phase 2)Ended earlyNCT03577028
What this trial is testing

Study of HPN424 in Patients With Advanced Prostate Cancer

Who this might be right for
Advanced Prostate Cancer
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 104
Testing effectiveness (Phase 2)Looking for participantsNCT05534646
What this trial is testing

Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer

Who this might be right for
Castration-resistant Prostate Cancer
Edwin Posadas, MD 100
Early research (Phase 1)Study completedNCT02655822
What this trial is testing

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

Who this might be right for
Renal Cell CancerMetastatic Castration Resistant Prostate Cancer
Corvus Pharmaceuticals, Inc. 502
Next Page